Spironolactone Ceva

RSS
Withdrawn

This medicine's authorisation has been withdrawn

spironolactone
MedicineVeterinaryWithdrawn
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for this product has been withdrawn due to the application of the sunset clause.

български (BG) (332.91 KB - PDF)

View

español (ES) (288.28 KB - PDF)

View

čeština (CS) (322.23 KB - PDF)

View

dansk (DA) (287.53 KB - PDF)

View

Deutsch (DE) (289.53 KB - PDF)

View

eesti keel (ET) (276.29 KB - PDF)

View

ελληνικά (EL) (335.21 KB - PDF)

View

français (FR) (289.25 KB - PDF)

View

hrvatski (HR) (307.68 KB - PDF)

View

latviešu valoda (LV) (334.28 KB - PDF)

View

Malti (MT) (324.47 KB - PDF)

View

Nederlands (NL) (287.82 KB - PDF)

View

polski (PL) (380.69 KB - PDF)

View

português (PT) (288.12 KB - PDF)

View

română (RO) (482.45 KB - PDF)

View

slovenčina (SK) (324.97 KB - PDF)

View

slovenščina (SL) (318.42 KB - PDF)

View

Suomi (FI) (285.73 KB - PDF)

View

svenska (SV) (287.15 KB - PDF)

View

Product information

български (BG) (936.84 KB - PDF)

View

español (ES) (457.64 KB - PDF)

View

čeština (CS) (695.23 KB - PDF)

View

dansk (DA) (443.55 KB - PDF)

View

Deutsch (DE) (456.17 KB - PDF)

View

eesti keel (ET) (460.88 KB - PDF)

View

ελληνικά (EL) (957.24 KB - PDF)

View

français (FR) (383.63 KB - PDF)

View

hrvatski (HR) (504.46 KB - PDF)

View

íslenska (IS) (622.5 KB - PDF)

View

italiano (IT) (614.01 KB - PDF)

View

latviešu valoda (LV) (750.12 KB - PDF)

View

lietuvių kalba (LT) (673.01 KB - PDF)

View

magyar (HU) (1.07 MB - PDF)

View

Malti (MT) (774.79 KB - PDF)

View

Nederlands (NL) (445.92 KB - PDF)

View

norsk (NO) (656.3 KB - PDF)

View

polski (PL) (1.09 MB - PDF)

View

português (PT) (456.69 KB - PDF)

View

română (RO) (807.04 KB - PDF)

View

slovenčina (SK) (711.68 KB - PDF)

View

slovenščina (SL) (702.28 KB - PDF)

View

Suomi (FI) (456.54 KB - PDF)

View

svenska (SV) (441.7 KB - PDF)

View
Latest procedure affecting product information: IAIN/0014
31/10/2012

български (BG) (299.51 KB - PDF)

View

español (ES) (219.22 KB - PDF)

View

čeština (CS) (262.67 KB - PDF)

View

dansk (DA) (227.42 KB - PDF)

View

Deutsch (DE) (218.75 KB - PDF)

View

eesti keel (ET) (221.16 KB - PDF)

View

ελληνικά (EL) (268.37 KB - PDF)

View

français (FR) (221.14 KB - PDF)

View

hrvatski (HR) (227.55 KB - PDF)

View

íslenska (IS) (185.95 KB - PDF)

View

italiano (IT) (191.92 KB - PDF)

View

latviešu valoda (LV) (256.74 KB - PDF)

View

lietuvių kalba (LT) (210.34 KB - PDF)

View

magyar (HU) (210.45 KB - PDF)

View

Malti (MT) (250.85 KB - PDF)

View

Nederlands (NL) (228.06 KB - PDF)

View

norsk (NO) (222.67 KB - PDF)

View

polski (PL) (245.92 KB - PDF)

View

português (PT) (231.37 KB - PDF)

View

română (RO) (434.62 KB - PDF)

View

slovenčina (SK) (253.67 KB - PDF)

View

slovenščina (SL) (237.31 KB - PDF)

View

Suomi (FI) (204.11 KB - PDF)

View

svenska (SV) (218.51 KB - PDF)

View

Product details

Name of medicine
Spironolactone Ceva
Active substance
spironolactone
International non-proprietary name (INN) or common name
spironolactone
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QC03DA01

Pharmacotherapeutic group

Diuretics

Therapeutic indication

For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.

Authorisation details

EMA product number
EMEA/V/C/000105
Marketing authorisation holder
Ceva Santé Animale

10 avenue de la Ballastière
33500 Libourne
France

Opinion adopted
17/04/2007
Marketing authorisation issued
20/06/2007
Revision
7

Assessment history

This page was last updated on

Share this page